 Bayer
wins second straight verdict in a Roundup cancer case
Send a link to a friend
[December 10, 2021]
By Tom Hals
(Reuters) - A California jury found that Bayer's Roundup weedkiller was
not the cause of a woman's non-Hodgkin's lymphoma, Bayer said on
Thursday, delivering the chemical giant its second trial victory over
claims the popular herbicide causes cancer.
|
|
 The jury in San Bernardino County found that Donnetta Stephens'
cancer was not caused by her exposure between 1985 and 2017 to
Roundup and its active ingredient glyphosate.
She sued the company for negligence and failing to warn her of the
dangers of Roundup.
"Despite everyone's best efforts, it was impossible to try a
coherent case via Zoom with our schedule," said Fletch Trammell,
Stephens' attorney. "We plan to appeal and look forward to trying
the case again in more favorable circumstances."
Trammell noted similar cases typically took weeks to try and the
Stephens case took more than four months due to technical problems
and long breaks.
Bayer said the verdict was consistent with the evidence.
The Stephens case is the fifth over Roundup to go to a trial
verdict.
Plaintiffs were awarded tens of millions of dollars in the first
three but Bayer got its first favorable trial outcome on Oct. 5,
which lifted the company's stock price.
[to top of second column] |
 The company said in May it
would be more selective in settling cases and
had said Stephens settlement demands were
unreasonable.
Roundup-related lawsuits have dogged the company
since it acquired the top-selling brand as part
of its $63 billion purchase of agricultural
seeds and pesticides maker Monsanto in 2018.
The company has spent billions of dollars to
settle around 96,000 Roundup cases of about
125,000.
Bayer is still pursuing appeals in two of the
three verdicts it lost, including one the
company hopes will be considered by the U.S.
Supreme Court, where a ruling for Bayer could
effectively end the Roundup cases.
(Reporting by Tom Hals in Wilmington, Delaware;
editing by Richard Pullin)
[© 2021 Thomson Reuters. All rights
reserved.] Copyright 2021 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content |
